CSL to acquire Novartis influenza vaccine business
Filed with ASX · · 14 pages · English
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has agreed to acquire Novartis’ global influenza vaccine business for US$275 million. The business will be combined with CSL’s subsidiary, bioCSL. Combining bioCSL’s existing influenza vaccine operations with the Novartis business will create the number two global player in the US$4 billion global influenza vaccine industry, with manufactu
Story so far
Earlier from CSL
- Chairman`s Address to Shareholders
- Recombinant Technologies
- Chairmans and MDs address to shareholders
- Announcement of buy-back
- Appointment of Paul Perreault as Executive Director
Later from CSL
- IDELVION(R) (rFIX-FP) - European Commission Approval
- Flucelvax Quadrivalent (Influenza Vaccine) - FDA Approval
- AFSTYLA (rFVIII-Single Chain) FDA approval
- 2016 FY Results Announcements and Analysts Briefing
- FDA Accepts BLA for Hereditary Angioedema Therapy
Follow CSL into a list and get an email when it puts out news.
Follow CSL